In the field of biomedicine, antibody-dependent cell-mediated cytotoxicity (ADCC), as a key mechanism in tumor immunotherapy, has always attracted the attention of many researchers. In order to meet the growing research needs, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully built an in vitro pharmacodynamics platform, among which the ADCC platform has won wide recognition in the industry with its unique features and advantages. This article will introduce in detail several major features of InnoModels' ADCC platform.
Diversified experimental service system
InnoModels' ADCC platform is first known for its diversified experimental service system. The platform can support combinatorial experiments on multiple types of tumor cells and immune cells. Whether it is tumor cell lines, primary tumor cells or genetically engineered cell lines, the platform can provide corresponding experimental conditions and technical support. This diversity not only meets the needs of different research projects, but also provides researchers with a wealth of options to choose the most appropriate cell type according to specific research goals.
In terms of effector cells, the platform also supports commercially derived PBMC (peripheral blood mononuclear cells) and clinical patient-derived PBMC. This support allows researchers to get closer to clinical reality and more accurately simulate the immune response process in the human body, thus improving the reliability and practicality of research.
Real simulation environment
In order to more truly reflect the actual situation of the ADCC process, InnoModels Bio's ADCC platform focuses on simulating the in vivo environment. The platform uses advanced cell culture technology and flow cytometry technology to monitor and record changes in cells during the experiment in real time. This technical method not only improves the accuracy of experiments, but also provides researchers with accurate and reliable data support, helping them to understand the details of the ADCC mechanism more deeply.

Highly customizable
InnoModels' ADCC platform is also highly customizable. The platform can customize personalized experimental plans according to the specific needs of researchers, including cell type, drug treatment, experimental time and other aspects. This flexibility enables the platform to meet the diverse needs of different researchers and provides powerful technical support for biomedical research. At the same time, it also avoids the "one size fits all" experimental model and improves the pertinence and efficiency of the research.
Efficient data processing capabilities
In addition to its advantages in experimental design and execution, InnoModels' ADCC platform is also equipped with an advanced data analysis system. This system can automatically process and analyze experimental data, greatly improving the efficiency and accuracy of data processing. Researchers can intuitively understand experimental results through the visual reports provided by the platform, thereby better guiding subsequent research work. This efficient data processing capability not only saves researchers time and energy, but also improves the overall quality and level of research.
Leading technological breakthroughs
InnoModels' innovation in the biomedical field is not only reflected in the ADCC platform, but also includes a series of other leading technological breakthroughs.For example, the company's iHuPDX in vivo drug efficacy model technology, based on xenograft technology of individual patient tumor cells, provides strong support for precision medicine. In addition, InnoModels Biotechnology has also successfully optimized a humanized mouse model of the PBMC immune system, achieving NK reconstruction close to clinical levels, providing a more reliable model for preclinical efficacy verification of NK-related immunotherapy drugs.
Conclusion
To sum up, InnoModels' ADCC platform plays an important role in biomedical research with its diversified experimental service system, realistic simulation environment, high degree of customizability, and efficient data processing capabilities. In the future, as the biomedical field continues to develop, InnoModels' ADCC platform will continue to leverage its unique advantages to promote the progress and innovation of biomedical research. At the same time, the company will continue to be committed to innovation and development in the biomedical field to bring good news to more patients.